Patients with ALS carrying the C9orf72 repeat expansion have been shown to exhibit remarkable clinical and pathological features suggesting that this hexanucleotide expansion identifies a distinct population of patients, with significant implications on therapeutic interventions design and screening for inclusion in clinical trials. Here, C9orf72 is linked to amyotrophic lateral sclerosis.